ABT-378: a second generation protease inhibitor. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


ABT-378: a second generation protease inhibitor.

BETA. 1998 Oct;:8, 55. Unique Identifier : AIDSLINE AIDS/99704474
Highleyman L

Abstract: ABT-378 is a second generation protease inhibitor currently undergoing clinical trials. It was developed by Abbott Laboratories and does not yet have a brand or generic name. ABT-378 was engineered to overcome some of the problems associated with the protease inhibitors currently on the market. Early results show it to be about 10 times more potent than Abbott's already-approved drug, Ritonavir. Cross resistance between ABT-378 and the other protease inhibitors appears to be low, but data is limited. When taken with Ritonavir, ABT-378 levels are raised significantly, which may allow for once or twice daily dosing. Early clinical test findings are summarized.
Keywords: NEWSLETTER ARTICLE Clinical Trials Drug Interactions Drug Therapy, Combination Drugs, Investigational HIV Protease Inhibitors/ADMINISTRATION & DOSAGE/*PHARMACOLOGY/ PHARMACOKINETICS Human Pyrimidinones/ADMINISTRATION & DOSAGE/*PHARMACOLOGY/ PHARMACOKINETICS Ritonavir/ADMINISTRATION & DOSAGE/PHARMACOLOGY/PHARMACOKINETICSKWDnewsletterarticleclinicaltrialsdruginteractionsdrugtherapy,combinationdrugs,investigationalhivproteaseinhibitors/administration&dosage/KWDpharmacology/pharmacokineticshumanpyrimidinones/administration&dosage/KWDpharmacology/pharmacokineticsritonavir/administration&dosage/pharmacology/pharmacokinetics
991230
A99C0632

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .